U.S. Markets closed

Sobi, Savient announce co-promotion agreement for Kineret in U.S.

Sobi and Savient announced that they have entered into an agreement for the co-promotion of Kineret in the U.S. Kineret, a recombinant IL-1 receptor antagonist, is a treatment for rheumatoid arthritis and indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active RA in patients 18 years of age or older who have failed one or more disease modifying antirheumatic drugs. Kineret is also indicated in the U.S. for the treatment of children and adults with the severe form of Cryopyrin-Associated Periodic Syndromes called Neonatal-Onset Multisystem Inflammatory Disease. Under the terms of the agreement, Sobi has granted to Savient the exclusive right to co-promote the sale of Kineret with Sobi in the U.S. Savient will market and promote Kineret beginning April 1. Sobi will remain responsible for all Kineret commercial drug manufacturing, supply, safety, and regulatory activities.